With training in Surgical Oncology, Radiotherapy, Chemotherapy, Molecular Biology and specializations in Head and Neck Cancer and Clinical Genetics, Dr. Ruben Cabanillas supports public and private institutions to integrate next generation sequencing and multiplatform molecular information into routine transdisciplinary patient care.

Professional Experience
  • Chief Medical Officer with Cabanillas Precision Consulting (2020-present)
    • Committed to making proactive, personalized healthcare a reality
  • Physician Advisor and Head Consultant of Clinical Genetics at IMOMA (2020-present)
    • Accountable for clinical management and genetic testing for a variety of conditions particularly cancer, deafness, blindness and rare diseases
  • Physician in Chief at IMOMA (2010-2020)
    • Responsible for multidisciplinary patient management, coordination of basic and translational research projects and institutional strategic planning
  • Visiting Professor at University of Oviedo (2006-2019)
    • Teaching at the Master of Biomedicine and Molecular Oncology and at the Health Sciences Area
  • Clinical Observerships at Memorial Sloan-Kettering Cancer Center (2005-2018)
    • Training in Head and Neck Surgery, Radiotherapy, Chemotherapy, Integrative Medicine and Molecular Oncology
  • Head of the Clinical and Translational Oncology Unit at IMOMA (2008-2010)
    • Entrusted with overseeing all inter-disciplinary procedures required to provide cutting-edge cancer diagnosis and treatments
  • Attending Physician at Hospital Universitario Central de Asturias (2006-2008)
    • Chairman of the Head and Neck Tumor Board
  • Human Geneticist Accreditation
  • Professional Master in Sports Medicine
  • European Master in Dietetics and Nutrition
  • Research Fellow in Biochemistry and Molecular Biology
  • Otorhinolaryngology and Head and Neck Surgery Board Certification
  • PhD. Doctor of Medicine and Surgery (Honors cum Laude with distinction)
  • M.D. Licensure in Medicine with Honors
Honors and awards
  • Corresponding Member of the The Royal Academy of Medicine of Asturias
  • Member of the Cancer Committee of the Principality of Asturias / Ministry of Health
  • Advisor of the Spanish Association Against Cancer
  • John M. Opitz 2012 Young Investigator Award
  • Best Doctoral Thesis (SEORL-CCC)
  • Extraordinary Doctorate Award
  • Extraordinary Graduate Award
  • First place at the National Health System Medical Licensing Examinations
  • Severo-Ochoa End of Degree Prize
Scientific production

Focused on multidisciplinary cutting-edge topics with near-term patient and/or public health benefits

  • More than 75 lectures and presentations
  • Over 40 peer-reviewed scientific articles
  • 15 book chapters and one book

PubMed publications

Selected publications

High clinical impact in cancer, aging and hereditary conditions

  • Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy. British Journal of Cancer. 2023
  • CANVAS: A new genetic entity in the otorhinolaryngologist’s differential diagnosis. Otolaryngol Head Neck Surg. 2022
  • Next-generation sequencing for identification of actionable gene mutations in intestinal-type sinonasal adenocarcinoma. Scientific Reports. 2021
  • Comprehensive diagnosis of inherited retinal and optical nerve disorders reveals hidden syndromes and personalized therapeutic options. J. Acta Ophthalmol. 2020
  • Clinical utility of next-generation sequencing in the aetiological diagnosis of sensorineural hearing loss in a Childhood Hearing Loss Unit. Acta Otorrinolaringol Esp. 2020
  • The pan-cancer landscape of co-amplification of the thyrosine kinases KIT/KDR/PDGFRA. The Oncologist. 2020
  • Sequencing results from multiple individuals of different ethnicities strongly question the existence of the KCNE1B pseudogene. J. Eur J Hum Genet. 2020
  • Insights into hypertrophic cardiomyopathy evaluation through a follow-up of a founder pathogenic variant. Rev Esp Cardiol. 2019
  • Comprehensive genomic diagnosis of non-syndromic and syndromic hereditary hearing loss in Spanish patients. J. BMC Med Genomics. 2018
  • A novel molecular diagnostics platform for somatic and germline precision oncology. J.Molecular Genetics and Genomic Medicine. 2017
  • Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Surgeons. Head and Neck. 2016
  • Cell-cell adhesion genes CTNNA2 and CTNNA3 are tumor suppressors frequently mutated in laryngeal carcinomas. Nature Communications. 2013
  • Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion. Nature Communications. 2013
  • Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variants. J Med Genet. 2013
  • Néstor-Guillermo progeria syndrome: A novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am J Med Genet A. 2011
  • Autophagy is essential for mouse sense of balance. J Clin Invest. 2010
  • Membrane-bound serine protease matriptase-2 is an essential regulator of iron homeostasis. Blood. 2008
  • Functional outcomes of transoral laser surgery of supraglottic carcinoma compared with a transcervical approach. Head and Neck. 2004
  • MCMPF’s Scientific Grant (2016-2019): “Analysis of the utility of the liquid biopsy for the identification of genomic alterations associated with response to targeted therapies and monitoring patients treated with radiotherapy”
  • MCMPF’s Scientific Grant (2014-2016): “Development of NGS platforms for the genetic diagnosis of hereditary deafness and blindness”
  • MCMPF’s Scientific Grant (2010-2014): “Translation of NGS technologies to the genomic characterization of progeria and cancer”
  • FIS: PI060069; 2007-2009: «Mechanisms of transcriptional response to TGFb1 in cancer»
  • FIS: PI030463; 2004-2006: “Functional characterization of the Hypoxia Inducible Factor (HIF 1a) and his target gene Calcium Channel Type T, in Head and Neck Squamous Cell Carcinomas”
Legal | Privacy Policy | Cookies Policy